Botulinum Neurotoxin Type B (BoNT/B) antibody
-
- Target See all Botulinum Neurotoxin Type B (BoNT/B) Antibodies
- Botulinum Neurotoxin Type B (BoNT/B)
- Reactivity
- Clostridium botulinum
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- Un-conjugated
-
Application
- Cell-ELISA (cELISA), Flow Cytometry (FACS)
- Specificity
- Anti-BoNT/B
- Purification
- Protein G
- Immunogen
- genetic immunisation with cDNA encoding BoNT/B
- Clone
- GR-3G7
- Isotype
- IgG1
-
-
- Application Notes
-
Flow cytometry: 1.2 µg/10^6 cells
CELISA: 1:200 - 1:400
For each application a titration should be performed to determine the optimal concentration. - Restrictions
- For Research Use only
-
- Concentration
- 2 mg/mL
- Buffer
- PBS, pH 7.2
- Handling Advice
- Avoid repeated freezing and thawing.
- Storage
- 4 °C
- Storage Comment
- short term: 2 °C - 8 °C, long term: -20 °C
-
- Target
- Botulinum Neurotoxin Type B (BoNT/B)
- Alternative Name
- BoNT B, Lightchain (BoNT/B Products)
- Target Type
- Bacteria
- Background
- Botulinum neurotoxin type B (BoNT/B) is produced by Clostridium botulinum, a genetically diverse class of anaerobic, spore-forming, gram-positive bacilli. Seven different botulinum toxin groups have been identified serologically and are called botulinum toxin type A,B,C,D,E,F, and G. BoNT/B is a two-chain polypeptide with a 100-kDa heavy chain, which is responsible for neurospecific binding joined by a disulphide bond to a 50-kDa light chain, a zinc-endopeptidase which blocks neurotransmitter release. BoNT/B is one of the most poisonous naturally occurring substances. It inhibits acetylcholine release from neuromuscular junctions while it is used as an important therapeutic mainstay in the treatment of spasticity disorders and as a cosmetic treatment.
-